IMVT

31.7402.40%
AJ

Andrew J. Fromkin

Director

Mr. Andrew J. Fromkin, also known as Drew, is CEO of Pulmovant. He serves as a Director at Immunovant, Inc. since October 2019 and as a Director of Immunovant Sciences Ltd. since October 2019. Since January 2021, he has served as the Vant Portfolio Operating Partner for Roivant Sciences, Inc., or RSI. From January 2021 until April 2023, Mr. Fromkin served as the Acting Chief Executive Officer of Proteovant Sciences, Inc. Mr. Fromkin served as Chief Executive Officer and President of Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) since March 2015 until September 30, 2020 and also served as its Interim Chairman until September 30, 2020. Mr. Fromkin served as the Chief Executive Officer and President of Trovis Pharmaceuticals LLC since May 12, 2006. Mr. Fromkin served as the Chief Executive Officer and President of Radius Health, Inc., from November 2013 to November 22, 2013. He served as the Chief Executive Officer of Clinical Data, Inc. from May 12, 2006 to May 2011 and served as its President from May 12, 2006 to April 13, 2011, where he joined on October 12, 2005. He served as Chief Executive Officer and President of Avalon Pharmaceuticals, Inc. since May 2009. He served as Chief Marketing Officer and Executive Vice President of Clinical Data Inc., from October 21, 2005 to May 2006. Mr. Fromkin was responsible for strategic commercialization initiatives including business development, reimbursement and medical economics, as well as new market strategies. He has experience in the health care industry in the areas of corporate development, strategic planning and sales and marketing management. He served as President and Chief Executive Officer of DoctorQuality, Inc., a leading provider of patient safety products and information services that was acquired by Quantros.Inc. Mr. Fromkin held several senior management roles at emerging healthcare companies, including executive appointments as President and Chief Executive Officer of Endo Surgical Devices, Inc., where his achievements include developing a line of innovative surgical devices, securing funding for Endo Surgical Devices, Inc. and guiding that company to its first FDA approval. Mr. Fromkin also was Vice President of Business Development and before that, Corporate Vice President of Business Development at Merck-Medco Managed Care, LLC, a wholly owned subsidiary of Merck & Co, Inc. In all of these roles, he successfully developed and negotiated complex transactions including major account sales, strategic alliances, joint ventures and acquisitions. Mr. Fromkin began his career in healthcare at Health Information Technologies as General Manager of its subsidiary, MCA and Director of Marketing and Payer Alliances for the parent company. He served as a Director at Regado Biosciences, Inc. since June 2014 until 2016. He served as a Director at Tobira Therapeutics, Inc. until November 1, 2016. He has been a Director of Tarveda Therapeutics, Inc. since April 2015. He serves as Director of Trovis Pharmaceuticals LLC. He served as a Member of the Board of Directors at Radius Health, Inc., since November 2013 until November 22, 2013. He served as Director of Avalon Pharmaceuticals, Inc. since May 2009. He served as an Executive Director of Clinical Data, Inc. from May 12, 2006 to April 13, 2011. Mr. Fromkin holds a B.A. Degree in Biology from Brandeis University.

Positions